Classification of vitreous detachment guides surgical procedure

Article

The surgical approach chosen by Borja Corcóstegui, MD, to repair vitreous detachments is driven by the classification of the detachment.

The surgical approach chosen by Borja Corcóstegui, MD, to repair vitreous detachments is driven by the classification of the detachment. In addition, use of anti-vascular endothelial growth factor (VEGF) and small-gauge instruments can be useful in vitreous detachment repair, said Dr. Corcóstegui, of the University of Barcelona, Spain.

The classification of the vitreous detachments that he uses ranges from Type 0 to Type 5:

• Type 0, characterized by complete posterior vitreous detachment (PVD).

• Type 1, characterized by one or more focal vitreoretinal attachments typically at the optic disc.

• Type 2, characterized by broad vitreoretinal attachments, with attachments larger than 1 disc area in size and the presence or absence of underlying traction with an associated complication rate.

• Type 3, characterized by vitreous attachment at the disc along the arcades and over the macula with surgical complication rates up to 7%.

• Type 4, characterized by vitreous attachment from the disc and major vascular arcades out to the extreme periphery, vitreous detached only over the macula and surgical complications up to 8% to 10%.

• Type 5, characterized by the absence of PVD with surgical complication rates of from 12% to 15%.

Grades 0, 1, 2, and 3 can be addressed with small-gauge instruments (23- or 25-gauge) and grades 4 and 5 with 20-gauge instruments. When operating on the eyes of patients with grades 2 to 5 vitreous detachments, 0.05 ml of either bevacizumab (Avastin, Genentech) or ranicizumab (Lucentis, Genentech) is injected 2 to 7 days preoperatively to decrease the proliferation of new vessels and shrink the collagen tissue.

Dr. Corcóstegui said he prefers 23-gauge instrumentation because he can operate through a small port and there is higher efficacy when cutting membranes.

"Recognizing the degree of vitreoretinal attachment can be useful and can help estimate the complicate rate," he said. "Anti-VEGF drugs are helpful to the surgical technique as well as small-gauge instrumentation."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
Related Content
© 2025 MJH Life Sciences

All rights reserved.